[背景]乙型病毒性肝炎相關慢加急性肝功能衰竭患者預后差病死率高。大多數預測肝衰竭預后的模型計算復雜且敏感性低。恩替卡韋治療乙型病毒性肝炎相關慢加急性肝功能衰竭報道較少。[目的]探討恩替卡韋治療乙型病毒性肝炎相關慢加急性肝功能衰竭的安全性和有效性。建立預測乙型病毒性肝炎相關性慢加急性肝功能衰竭患者預后的預測模型（Tongji prognostic predictor model, TPPM）。[方法]共有248例乙型病毒性肝炎相關慢加急性肝功能衰竭患者納入本回顧性研究。其中124例在內科標準治療的基礎上加用恩替卡韋,另外124例患者只進行內科標準治療但不使用核苷類似物抑制病毒�？共《局委熃M和對照組在基線病毒學、臨床生化等均無顯著差異。收集患者生存期、生化指標、凝血功能、血液常規(guī)檢查、血清學指標、病毒學指標和并發(fā)癥等臨床數據,通過多因素回歸分析建立預測預后的回歸模型—同濟預后預測模型（Tongji prognostic predictory model, TPPM）。[結果]恩替卡韋治療組患者1月和3月生存率分別為72.58%（90/124）和61.29%（76/124）,顯著高于對照組的... 

【文章來源】：華中科技大學湖北省 211工程院校 985工程院校 教育部直屬院校

【文章頁數】：95 頁

【學位級別】：博士

【文章目錄】：
英文縮略語對照表
中文摘要
英文摘要
恩替卡韋治療乙肝病毒相關慢加急性肝功能衰竭的臨床研究
    1. 背景
    2. 患者與方法
    3. 結果
    4. 討論
    結論
A Clinical Study of Entecavir Treatment In Patients With HBV RelatedAcute-On-Chronic Liver Failure
    1.Background
    2.Patients and Methods
    3.RESULTS
    4.Discussion
    Conclusion
參考文獻
綜述：抗病毒治療在預防和治療乙肝病毒相關肝細胞癌中的作用研究進展
    參考文獻
博士研究生期間發(fā)表的論文
會議摘要
致謝


【參考文獻】：
期刊論文
[1]原發(fā)性肝癌規(guī)范化診治的專家共識[J]. 楊秉輝,叢文銘,周曉軍,陳孝平,楊甲梅,樊嘉,王建華,楊仁杰,李槐,蔣國梁,曾昭沖,陳敏華,陳敏山,梁萍,呂明德,羅榮城,劉魯明,秦叔逵,葉勝龍.  實用肝臟病雜志. 2009(05)
[2]Short-term entecavir therapy of chronic severe hepatitis B[J]. Jun Chen,Jian-Hua Han,Chun Liu,Ren-He Yu,Fa-Zhao Li, Qun-Fang Li and Guo-Zhong Gong Liver Diseases Center,Second Xiangya Hospital, Central South University,Changsha 410011,China;Department of Epidemics and Health Statistics,School of Public Health,Central South University,Changsha 410078,China.  Hepatobiliary & Pancreatic Diseases International. 2009(03)
[3]Fibrinogen-like protein 2/fibroleukin prothrombinase contributes to tumor hypercoagulability via IL-2 and IFN-γ[J]. Kai Su,Fang Chen,Wei-Ming Yan,Qi-Li Zeng,Li Xu,Dong Xi,Bin Pi,Xiao-Ping Luo,Qin Ning,Department of Infectious Diseases and Pediatrics,Institute of Infectious Diseases,Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology,1095 Jiefang Avenue,Wuhan 430030,Hubei Province,China.  World Journal of Gastroenterology. 2008(39)
[4]Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide,carboplatin,epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil:A pilo[J]. Toru Ishikawa,Michitaka Imai,Hiroteru Kamimura,Atsunori Tsuchiya,Tadayuki Togashi,Kouji Watanabe,Kei-ichi Seki,Hironobu Ohta,Toshiaki Yoshida,Tomoteru Kamimura.  World Journal of Gastroenterology. 2007(41)
[5]The MELD scoring system for predicting prognosis in patients with severe hepatitis after plasma exchange treatment[J]. Jian-Wu Yu,Gui-Qiang Wang,Yong-Hua Zhao,Li-Jie Sun, Shu-Qin Wang and Shu-Chen Li Department of Infectious Diseases,Second Affiliated Hospital,Harbin Medical University,Harbin 150086,China ;and Department of Infectious Diseases,First Hospital of Peking University,Beijing 100034,China.  Hepatobiliary & Pancreatic Diseases International. 2007(05)
[6]肝衰竭診療指南[J]. Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association..  中華肝臟病雜志. 2006(09)
[7]Fibrinogen-like protein 2 fibroleukin expression and its correlation with disease progression in murine hepatitis virus type 3-induced fulminant hepatitis and in patients with severe viral hepatitis B[J]. Gary Levy.  World Journal of Gastroenterology. 2005(44)
[8]慢性乙型肝炎治療——困難和出路[J]. 徐克成,危北海,姚希賢,張萬岱,陳治水,陳澤民,李道本,王冠庭.  中國中西醫(yī)結合消化雜志. 2002(01)
[9]重型肝炎命名和診斷分型的再認識──附477例臨床分析[J]. 王宇明,陳耀凱,顧長海,蔣黎,向德棟.  中華肝臟病雜志. 2000(05)



本文編號：2987267